Open with the portfolio-level pattern: the foundational CRISPR estate sits with institutions, not operating companies. In the C12N gene-editing record, the largest non-agricultural assignees include the Regents of the University of California, the Broad Institute, the President and Fellows of Harvard College, and the General Hospital Corporation. The commercial players — CRISPR Therapeutics, Sangamo, Regeneron — appear, but the deepest foundational holdings trace to academic institutions. That is the structural fact behind every CRISPR licensing conversation.
Filing velocity in C12N has climbed steadily, with the gene-editing record showing its heaviest grant years in the 2020s. That is not surprising for a platform moving from discovery to product, but the strategic implication is specific: the volume is increasingly in applied claims — particular guide RNAs, delivery configurations, and system refinements — layered on top of the foundational machinery claims. The base layer is set; the growth is in the application layer.
A representative applied grant illustrates the pattern. The General Hospital Corporation's US10119133B2, "Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing" (issued November 6, 2018; CPC C12N 15/102), does not claim CRISPR itself — it claims a specific improvement, shorter guide RNAs that reduce off-target editing. This is the shape of the modern filing: take the foundational system as given and claim a measurable improvement to it.
Newer entrants are filing whole-system claims too. US12157886B2, "Type II CRISPR/Cas9 genome editing system and the application thereof" (Zhuhai Shu Tong Medical Technology, issued December 3, 2024; CPC C12N 15/111), claims a Cas9 editing system and its application. The arrival of system-level claims from newer assignees, years after the foundational grants, signals a field where the basic platform is open enough to invite fresh system claims around specific configurations and uses.
Distinguish a thicket from a moat here. A defensive thicket is a dense layer of narrow improvement claims that raise the cost of operating freely without any single claim being decisive; a moat is one or a few broad claims that genuinely block. The CRISPR landscape looks more like an institutionally-owned foundation plus a commercial thicket of improvements than like a single corporate moat. Freedom-to-operate analysis therefore has to clear both the institutional base layer (via license) and the surrounding improvement claims.
The strategist's conclusion: do not read CRISPR IP as a corporate-versus-corporate war. Read it as an institutional foundation — UC, Broad, Harvard, General Hospital — beneath a growing thicket of applied, company-and-institution improvement claims. The filing velocity says the platform war's foundational phase is largely settled into licensing; the live competition is now in the application-layer claims, where specific guide designs and delivery methods are the contested ground.